U
ANTH

UBS’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

UBS’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$8K Sell
531
-1,856
-78% -$39.1K ﹤0.01% 9097
2014
Q2 		$65K Sell
2,387
-1,096
-31% -$27.1K ﹤0.01% 6513
2014
Q1 		$93K Buy
3,483
+318
+10% +$8.08K ﹤0.01% 6081
2013
Q4 		$78K Buy
3,165
+46
+1% +$1.19K ﹤0.01% 6385
2013
Q3 		$100K Sell
3,119
-627
-17% -$19.4K ﹤0.01% 6024
2013
Q2 		$111K Buy
+3,746
New +$140K ﹤0.01% 5782

Other funds holding ANTH

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

UBS's ANTH Position: Q3 2014 in Review

UBS reduced its Anthera Pharmaceuticals, Inc. (ANTH) stake by 78% in Q3 2014, selling an estimated $39.1K and leaving 531 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #9097.

UBS first reported a position in ANTH in Q2 2013 and has held it in 6 quarters since. The position peaked at $111K in Q2 2013. 35 funds tracked by Wall St. Rank hold ANTH as of Q3 2014.

  • UBS held 531 shares of Anthera Pharmaceuticals, Inc. worth $8K as of Q3 2014.
  • UBS sold 1,856 Anthera Pharmaceuticals, Inc. shares in Q3 2014, an estimated $39.1K.
  • Anthera Pharmaceuticals, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9097 holding.
  • UBS first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2013 and has held it in 6 quarters since.
  • UBS's Anthera Pharmaceuticals, Inc. position peaked at $111K in Q2 2013.
  • 35 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.